Skip to main content

Table 2 Table 1

From: The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19

Model Effect of imatinib Reference
In vitro studies   
Rat aortic endothelial cells Protects endothelial barrier [20]
Human umbilical vein endothelial cells Protects endothelial barrier Improves cell-matrix adhesion [3]
Human lung microvascular endothelial cells Protects endothelial barrier [3]
Immortalized endothelial cells Protects endothelial barrier [9]
Human umbilical vein endothelial cells Protects endothelial barrier [18]
Mouse lung microvascular endothelial cells Protects endothelial barrier [40]
In vivo studies   
Bleomycin-induced lung injury Anti-inflammatory
Anti-fibrotic
[35]
Isolated perfused lung model (mouse) Inhibits lung vascular leak [3]
Miles assay (mouse) Attenuates vascular leak in skin [3]
Cecal Ligation & Puncture (Sepsis) (mouse) Attenuates vascular leak in lungs, kidneys [3]
Intratracheal LPS (mouse) Attenuates pulmonary edema [18]
Ischemia-reperfusion in reperfusion lung Reduces endothelial cytotoxicity [40]
Miles assay (mouse) Attenuates vascular leak in skin [9]
Intratracheal LPS (mouse) Attenuates vascular leak and inflammation [23]
Cardiac bypass surgery Attenuates vascular leak, improves perfusion, improves oxygenation [19]
Clinical case reports (human)   
Pulmonary veno-occlusive disease Resolution of pulmonary edema
Improvement of oxygenation
[30]
Bleomycin-induced pneumonitis / lung injury Resolution of pulmonary edema [8]
Idiopathic pulmonary vascular leak Resolution of generalized edema
Reduction of pulmonary vascular leak
Aman 2013
Drug-induced pneumonitis Resolution of pneumonitis, case series [22]